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http://dx.doi.org/10.1016/j.ccr.2014.03.017SUMMARYTo identify regulatory drivers of prostate cancer malignancy, we have assembled genome-wide regulatory
networks (interactomes) for human and mouse prostate cancer from expression profiles of human tumors
and of genetically engineered mouse models, respectively. Cross-species computational analysis of these
interactomes has identified FOXM1 and CENPF as synergistic master regulators of prostate cancer malig-
nancy. Experimental validation shows that FOXM1 and CENPF function synergistically to promote tumor
growth by coordinated regulation of target gene expression and activation of key signaling pathways
associated with prostate cancer malignancy. Furthermore, co-expression of FOXM1 and CENPF is a robust
prognostic indicator of poor survival andmetastasis. Thus, genome-wide cross-species interrogation of reg-
ulatory networks represents a valuable strategy to identify causal mechanisms of human cancer.INTRODUCTION
It is widely appreciated that cancer is not a single entity but rather
a highly individualized spectrum of diseases characterized by aSignificance
Genetically engineered mouse models have been widely used
ical investigations. However, inherent species differences often
mice to human cancer. Here we introduce a strategy using cro
latory networks for the effective integration of experimental find
enables the identification of conserved master regulators of m
ergistic interaction. This computational paradigm should be br
cer, as well as integrating preclinical analyses from mouse to
638 Cancer Cell 25, 638–651, May 12, 2014 ª2014 Elsevier Inc.large number of molecular alterations (Hanahan and Weinberg,
2011). Distinguishing those that constitute true drivers of cancer
phenotypes from the multitude that are simply deregulated has
proven to be a daunting task, which is further exacerbated byfor in vivo analyses of cancer phenotypes as well as preclin-
hinder the appropriate extrapolation of studies performed in
ss-species computational analysis of context-specific regu-
ings frommouse models and human cancer. This approach
alignant prostate cancer, as well as elucidation of their syn-
oadly applicable for elucidating causal mechanisms of can-
man.
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tically to elicit cancer phenotypes. In this regard, prostate cancer
is particularly challenging because its notorious heterogeneity,
combined with a relative paucity of recurrent gene mutations,
has made it especially difficult to identify molecularly distinct
subtypes with known clinical outcomes (Baca et al., 2013;
Schoenborn et al., 2013; Shen and Abate-Shen, 2010). Addition-
ally, whereas most early-stage prostate tumors are readily
treatable (Cooperberg et al., 2007), advanced prostate cancer
frequently progresses to castration resistance, which is often
metastatic and nearly always fatal (Ryan and Tindall, 2011; Scher
and Sawyers, 2005). Thus, there is a pressing need to identify
bona fide determinants of aggressive prostate cancer as well
as prognostic biomarkers of disease outcome.
Analysis of genetically engineered mouse models (GEMMs)
can circumvent inherent challenges associated with the intrinsic
complexity of more heterogeneous human cancer phenotypes.
Indeed, investigations of mouse models of prostate cancer
have contributed to characterization of disease-specific path-
ways, led to the identification of biomarkers of disease progres-
sion, and provided useful preclinical models for prevention and
therapy (Irshad and Abate-Shen, 2013; Ittmann et al., 2013).
Following the description of an initial transgenic model nearly
20 years ago, there are now numerous GEMMs that collectively
model key molecular pathways deregulated in human prostate
cancer and recapitulate the various stages of disease pro-
gression, including preinvasive lesions (prostatic intraepithelial
neoplasia; PIN), adenocarcinoma, castration resistance, and
metastasis (Irshad and Abate-Shen, 2013; Ittmann et al., 2013).
However, inherent species differences often hinder direct
comparative analyses of mouse models and human cancer.
Indeed, such analyses would greatly benefit from computa-
tional approaches that enable accurate cross-species inte-
gration of regulatory information from mouse to man. Recent
advances in systems biology have led to the reverse engineer-
ing of regulatory networks (interactomes) that integrate large-
scale data sets encompassing expression profiles, protein-pro-
tein interactions, genomic alterations, and epigenetic changes
associated with cancer and other diseases (Lefebvre et al.,
2012). However, whereas individual analyses of human and
murine interactomes have led to relevant biological discoveries,
their cross-species interrogation has not been systematically
implemented.
Here, we introduce an approach for accurate cross-species
analysis of conserved cancer pathways based on reverse
engineering of genome-wide regulatory networks (i.e., interac-
tomes) representing both human and mouse prostate cancer.
To accomplish this, we have produced a regulatory network
based on in vivo perturbation of a repertoire of mouse cancer
models and implemented comparative analysis with a comple-
mentary regulatory network generated from human prostate
cancer data sets. Cross-species computational interrogation of
these paired interactomes, followed by experimental and clinical
validation, has elucidated the synergistic interaction of FOXM1
and CENPF as a driver of prostate cancer malignancy. We
propose that analyses of genome-wide, cross-species regula-
tory networks will provide an effective paradigm for elucidating
causal mechanisms of human cancer and other complex
diseases.RESULTS
We developed a strategy for genome-wide interrogation of can-
cer phenotypes based on accurate integration of experimental
data from model organisms and human cancer (Figure 1). First,
we generated regulatory networks (interactomes) for human
and mouse prostate cancer using the Algorithm for the Recon-
struction of Accurate Cellular Networks (ARACNe; Basso et al.,
2005; Margolin et al., 2006b). We next evaluated the suitability
of these mouse and human interactomes for cross-species
interrogation using a computational approach to assess the
global conservation of their transcriptional programs. We then
used the Master Regulator Inference algorithm (MARINa; Carro
et al., 2010; Lefebvre et al., 2010) to infer candidate master reg-
ulators that act individually or synergistically to drive malignant
prostate cancer. Finally, we performed experimental studies
to validate synergistic interactions of master regulators, to
elucidate underlying mechanisms, and to evaluate their clinical
relevance.
Assembly of Interactomes for Human and Mouse
Prostate Cancer
ARACNe is an unbiased algorithm that infers direct transcrip-
tional interactions based on the mutual information between
each transcriptional regulator and its potential targets. For
optimal analyses, ARACNe requires large data sets of gene
expression profiles (R100) having significant endogenous (i.e.,
genetic) and/or exogenous (i.e., perturbation-induced) hetero-
geneity. To assemble a human prostate cancer interactome,
we analyzed the expression profile data set reported elsewhere
(Taylor et al., 2010), which is ideally suited for ARACNe because:
(1) it is relatively large (n = 185) and diverse, including primary
tumors, adjacent normal tissue, metastases, and cell lines; (2)
its primary tumors encompass the full range of pathological
Gleason scores and have well-annotated clinical outcome
data; and (3) it displays extensive genetic diversity and tumor
heterogeneity, as shown by t-Distributed Stochastic Neighbor
Embedding (t-SNE) analysis (Figure 2; Table S1 available online).
Notably, interactomes assembled from three alternative human
prostate cancer data sets (Table S1) were neither as complete
nor as extensive (data not shown).
To assemble a corresponding mouse prostate cancer interac-
tome, it was first necessary to generate an expression profile
data set of appropriate size and representing sufficient expres-
sion variability. We selected 13 distinct GEMMs, which together
represent the full spectrum of prostate cancer phenotypes,
including normal epithelium (wild-type), low-grade PIN (Nkx3.1
and APT), high-grade PIN, and adenocarcinoma (APT-P, APC,
Myc, NP, Erg-P, and NP53), castration resistance (NP-AI), and
metastatic prostate cancer (NPB,NPK, and TRAMP; Figure S1A;
Table S2). To further increase the variability of the expression
profiles, we introduced a controlled set of exogenous pertur-
bations by in vivo administration of 13 small-molecule pertur-
bagens to each GEMM. Perturbagens were selected for their
clinical relevance and/or ability to modulate key prostate cancer
pathways, including hormone signaling (testosterone, calcitriol,
and enzalutamide); PI3 kinase activity (MK2206, LY294002,
and rapamycin); MAP kinase activity (PD035901); tyrosine kinase
activity (imatinib, dasatinib, and sorafenib); NFkB signalingCancer Cell 25, 638–651, May 12, 2014 ª2014 Elsevier Inc. 639
Figure 1. Strategy for Genome-wide Cross-
Species Analyses of Prostate Cancer
Schematic representation of the overall strategy.
Step I: assembly of human and mouse prostate
cancer interactomes. Step II: genome-wide
computational analysis of conservation of tran-
scriptional regulon activity in the mouse and
human prostate cancer interactomes. Step III:
master regulator analysis for identification of
conserved master regulators and prediction of
synergy. Step IV: validation of candidate master
regulators using functional, molecular, and clinical
analyses.
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Figure 2. Heterogeneity of Human and Mouse Data Sets Used for Interactome Assembly
t-Distributed Stochastic Neighbor Embedding (t-SNE) analysis of human and mouse data sets used to assemble the prostate cancer interactomes. (Left) t-SNE
analysis of the Taylor data set relative to Gleason score (GS). (Middle) Schematic representation of GEMMs used to assembly the mouse prostate cancer
interactome. t-SNE analysis showing relative distribution of the GEMMs. (Right) Schematic diagram depicting perturbagens used to treat the GEMMs. t-SNE
analysis showing the relative distribution of perturbagens for a representative GEMM (i.e., the NP mice).
See also Figure S1 and Tables S1 and S2.
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(docetaxel; Supplemental Experimental Procedures). Following
pilot studies to define appropriate doses and schedule (Figures
S1B–S1D), we adopted a universal treatment schedule of one
treatment per day for 5 days with dosage determined inde-
pendently for each perturbagen (Supplemental Experimental
Procedures).
The resulting data set comprises 384 gene expression profiles,
corresponding to the 13 GEMMs each treated with the 13 per-
turbagens or vehicles. t-SNE analysis revealed that the resulting
mouse data set represented an extensive range of expression
variability, as required for ARACNe (Figure 2). Specifically,
whereas expression profiles from the same GEMMs and
perturbagens clustered together, the diverse GEMMs and per-
turbagens provided independent and highly effective axes to
modulate gene expression variability.
ARACNe was run independently on the human and mouse
data sets using a conservative mutual information threshold
(p % 1.0 3 109, i.e., p % 0.05 Bonferroni corrected for all
candidate interactions). This resulted in highly robust regulatory
networks—in particular, the ‘‘human interactome’’ represented
249,896 interactions between 2,681 transcriptional regulators
and their inferred target genes (Figure 3A; Table S3), whereas
the ‘‘mouse interactome’’ represented 222,787 interactions for
2,072 transcriptional regulators (Figure 3A; Table S4).
Analysis of Genome-wide Conservation of
Transcriptional Regulatory Pathways
Because it has been previously established that target-by-target
analysis may not be optimal to evaluate cross-species interac-
tome conservation (e.g., Zhang et al., 2012), we developed a
quantitative metric to compare conservation of the human and
mouse interactomes. In particular, we developed a modificationof theMARINa algorithm that allows for single-sample analysis to
infer the differential activity of all 2,028 transcriptional regulators
represented in both interactomes. Analysis was performed on
1,009 expression profiles across the four human data sets (Table
S1) and the mouse data set (described herein) to determine
whether the inferred activities of each regulator were significantly
correlated (p % 0.05), indicating that the murine and human
regulatory programs were conserved (Supplemental Experi-
mental Procedures). The accuracy of this metric was evident
by comparing two equivalent same-species interactomes from
the human and mouse data sets (i.e., positive controls), in which
virtually all transcriptional regulators were conserved (>90%), in
contrast to randomized interactomes (i.e., negative controls),
which had virtually no conservation (Figure 3B).
Using this metric, we found that 70%of the transcriptional reg-
ulators in the human and mouse prostate cancer interactomes
regulate statistically conserved programs (p% 0.05; Figure 3C;
Table S5). Notably, among the conserved transcriptional regula-
tors are many genes important in prostate cancer, such as AR,
ETS1, ETV4, ETV5, STAT3, MYC, BRCA1, and NKX3.1 (Shen
and Abate-Shen, 2010; Figure 3A; Table S5). In particular, AR
displayed extensive correlation of its transcriptional activity
between the human and mouse interactomes (Figure 3D),
consistent with its known role as a key regulator of prostate
development and tumorigenesis (Ryan and Tindall, 2011; Shen
and Abate-Shen, 2010).
Cross-Species Computational Analysis Identifies
Synergistic Master Regulators of Malignant Prostate
Cancer
To identify master regulators (MRs) of malignant prostate cancer
(Figure 4), we used the MARINa algorithm, which identifies
candidate MRs based on the concerted differential expressionCancer Cell 25, 638–651, May 12, 2014 ª2014 Elsevier Inc. 641
Figure 3. Genome-wide Conservation Ana-
lyses of the Human and Mouse Prostate
Cancer Interactomes
(A) ARACNe subnetworks from the human and
mouse prostate cancer interactomes highlighting
selected conserved transcriptional regulators. The
scaled size of the transcriptional regulator nodes
(colored circles) indicates the degree of conser-
vation while the relative distance between them
approximates the strength of their association.
(B and C) Histograms (density plots) showing
conservation of transcriptional regulator activity
between the human and mouse prostate can-
cer interactomes. (B) Distribution of correlation
coefficients of activity profiles of transcriptional
regulators for randomized interactomes (negative
control; purple line) and the positive control inter-
actomes for human (yellow) and mouse (green;
Supplemental Experimental Procedures). (C) Dis-
tribution of Z score for conservation of activity
profiles between the human and mouse inter-
actomes at p% 0.05.
(D) Comparison of the androgen receptor (AR)
activity levels in each sample from Taylor et al.
(top) and the mouse data set (bottom) showing the
Spearman correlation coefficient.
See also Tables S3, S4, and S5.
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activity, DA). Specifically, ‘‘activated’’ MRs have positively regu-
lated and repressed targets significantly enriched among over-
and underexpressed genes, respectively, while ‘‘repressed’’
MRs have the converse. We interrogated the human prostate
cancer interactome using a gene signature representing prostate
cancer malignancy derived from the Taylor data set as described
elsewhere (Aytes et al., 2013), which compares aggressive
prostate tumors (Gleason score R 8 with rapid biochemical
recurrence; n = 10) to indolent ones (Gleason score 6 tumors
with no biochemical recurrence; n = 39). This analysis identified
175 candidate MRs, including 49 activated and 126 repressed
(p% 0.05; Figure 4A; Table S6).
To investigate the robustness of these MRs, we performed
MARINa analysis using an independent malignancy signature
derived from the Balk data set (Table S1; Stanbrough et al.,642 Cancer Cell 25, 638–651, May 12, 2014 ª2014 Elsevier Inc.2006), which compares castration-resis-
tant (n = 29) with hormone-naive disease
(n = 22). The MRs identified from the Balk
malignancy signature (Table S6) signifi-
cantly overlapped with those identified
from the Taylor malignancy signature
(36 in common; Fisher exact test p <
0.0001; Table S6). Furthermore, MARINa
analyses of 15 independent interactomes
revealed that the MRs inferred from two
independent prostate cancer interac-
tomes significantly overlapped with those
inferred from the Taylor prostate cancer
interactome (p < 7 3 109 and p < 8 3
1020, Fisher exact test), whereas the
overlap of MRs inferred from 13 nonpros-tate cancer-specific interactomes were orders of magnitude less
significant (Supplemental Experimental Procedures). Thus, MRs
of human prostate cancer malignancy are consistent across
independent prostate cancer malignancy signatures, but depen-
dent on a context-specific prostate cancer interactome.
To identify corresponding mouse MRs of malignancy, we per-
formedMARINa analysis on four independent GEMMsignatures,
which embody the diverse range of prostate cancer phenotypes
represented among the GEMMs (Figure S2A; Table S2; Supple-
mental Experimental Procedures). Meta-analysis of the resulting
MRs from these independent GEMM signatures led to identifica-
tion of 229 candidate mouse MRs, including 110 activated and
119 repressed MRs (p% 0.001; Figure 4A; Table S7).
The independent list of human and mouse MRs were then in-
tegrated to produce a ranked list of 20 conservedMRs, including
seven activated and 13 repressed (joint p value: p% 0.0074 by
Figure 4. Conserved Master Regulators of Malignant Prostate Cancer
(A) (left) Master regulators (MRs) were identified using human or mouse malignancy signatures; differential activity (DA) is based on enrichment of activated (red)
and repressed (blue) targets. DE, differential expression. (Right) Venn diagram showing integration of independent lists of activated MRs from human (49) and
mouse (110) with an overlap of seven conserved MRs. Clinical features of all human MRs versus the conserved MRs showing the percentage associated with
disease outcome (using a COX proportional hazard model) and the percentage that are differentially expressed in advanced prostate cancer (from Oncomine).
(B) Conserved activated MRs are shown for the human (left) and mouse (right) malignancy signatures, depicting their positive (activated; red bars) and negative
(repressed; blue bars) targets. The ranks of differential activity (DA) and differential expression (DE) are shown by the shaded boxes; the numbers indicate the rank
of the DE in the malignancy signature.
(C) Summary of conservedMRs showing joint p value from human andmouseMARINa analysis, calculated using Stouffer’s method; p value for COX proportional
hazard regression model applied to mRNA expression levels and predicted MR activity; and average p values for differential expression of MRs in metastatic
versus nonmetastatic primary tumors.
(D) Computational synergy analysis depicting FOXM1 and CENPF regulons from the human (left) and mouse (right) interactomes showing shared and nonshared
targets. Red corresponds to overexpressed targets and blue to underexpressed targets; the p value for the enrichment of shared targets is shown.
See also Figure S2 and Tables S6 and S7.
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these conservedMRsweremore likely to be associated with dis-
ease outcome than the nonconserved ones, as assessed by a
univariate COX proportional hazard regression model (p %
0.05), and were also more likely to be differentially expressedin aggressive prostate tumors (Figures 4A and 4C; Supplemental
Experimental Procedures).
We focused our subsequent analysis on the activated
conserved MRs, each of which has been associated with can-
cer-related biological processes: CHAF1A (chromatin activity);Cancer Cell 25, 638–651, May 12, 2014 ª2014 Elsevier Inc. 643
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Genome-wide Regulatory Networks of Prostate CancerTRIB3 (regulation of cell signaling in transcriptional control);
FOXM1 (cell cycle progression); CENPF (mitosis); PSRC1
(growth control); TSFM (translational elongation); and ASF1B
(regulation of nucleosome assembly; Figure 4B). We further
prioritized these MRs by computationally evaluating their poten-
tial synergistic interactions. In particular, any pair of MRs was
considered ‘‘synergistic’’ if their coregulated ARACNe-inferred
targets were more significantly enriched in the malignancy
signature than in their individual targets (p % 0.001; Carro
et al., 2010; Lefebvre et al., 2010). Among all possible pairs of
conserved activated MRs, the only pair that was statistically
significant was FOXM1 and CENPF (Figure 4D). Notably, both
FOXM1 and CENPF are expressed in aggressive prostate
tumors and predicted to be associated with disease outcome
(Figure 4C; Supplemental Experimental Procedures). Strikingly,
among all activated (rather than conserved) human MRs
identified, only FOXM1 and CENPF were predicted to be both
synergistic and of potential clinical relevance (Supplemental
Experimental Procedures). Thus, cross-species analyses of
conserved MRs identified a single MR synergy pair of potential
clinical relevance.
Cosilencing FOXM1 and CENPF Synergistically
Abrogates Prostate Tumor Growth
To evaluate their individual and potential synergistic functions in
prostate cancer, we silenced FOXM1 and/or CENPF individually
or together in four human prostate cell lines, DU145, PC3,
LNCaP, and 22Rv1, which have differing tumorigenic properties
and responses to androgen signaling (Figure 5A; Figure S3A).
Notably, each of these cell lines express high levels of FOXM1
and CENPF mRNA; however, LNCaP does not have detectable
CENPF protein (Figure 5B; Figures S3B–S3E), and therefore
provides an excellent negative control for synergy analysis. To
silence FOXM1 and/or CENPF, we engineered doxycycline-
inducible lentiviral vectors expressing shRNAs for FOXM1 or
CENPF or a control shRNA, as well as an RFP or GFP reporter
(Figure 5A; Supplemental Experimental Procedures); analyses
were done using two independent shRNA to minimize concerns
about off-target effects (Figure S3). We distinguish ‘‘synergistic’’
versus ‘‘additive’’ effects of FOXM1 and CENPF by first extrap-
olating their ‘‘predicted additivity’’ based on their individual
silencing using a log-linear model, and then comparing this pre-
dicted value to the ‘‘actual’’ (observed) effect following their co-
silencing using a one-sample t test; if the ‘‘actual’’ is statistically
greater than the ‘‘predicted additive,’’ we conclude that FOXM1
and CENPF are synergistic rather than additive (Supplemental
Experimental Procedures).
Whereas individual silencing of FOXM1, and, to a lesser
extent, CENPF, resulted in reduced cellular proliferation, the
actual reduction following their cosilencing was statistically
greater (p < 0.01; one-sample t test) than the predicted additive,
and is therefore synergistic for each cell line that expresses both
FOXM1 and CENPF proteins (Figure S3F). Similarly, with respect
to colony formation, whereas individual silencing of FOXM1
or CENPF reduced the number of colonies, their cosilencing
resulted in nearly complete abrogation of colony formation in
each cell line expressing both FOXM1 and CENPF proteins
(p < 0.001; one-sample t test; Figures 5C and 5D; Figures S3G
and S3H). Importantly, cosilencing of FOXM1 and CENPF was644 Cancer Cell 25, 638–651, May 12, 2014 ª2014 Elsevier Inc.not associated with reduced viability, apoptosis, or further cell
cycle arrest relative to their individual silencing (Figures S3I–
S3K), suggesting that their observed synergy was not simply
due to induction of cell death or was secondary to cell cycle
arrest.
To investigate their consequences for tumor growth in vivo, we
engrafted DU145 cells expressing silencing vectors for FOXM1
and/orCENPF (or controls) into immunodeficient mice andmoni-
tored tumor growth (Figures 5E–5H). Consistent with the cell cul-
ture studies, individual silencing of FOXM1 or CENPF resulted
in a modest but statistically significant reduction in tumor growth
(2-fold, p% 0.002 and 1.5-fold, p% 0.002, respectively), as well
as tumor weight (2.3-fold, p % 0.007, and 1.6 fold, p % 0.01,
respectively) (Figures 5F and 5G). However, cosilencing of
FOXM1 and CENPF resulted in a complete abrogation of tumor
growth (10.2-fold reduced, p%0.000013) and a profound reduc-
tion in tumor weight (12.9-fold, p % 0.000011; Figures 5F and
5G). Notably, the actual inhibition of tumor growth following
cosilencing of FOXM1 and CENPF was significantly greater
than the predicted additive inhibition (3.3-fold difference, p %
0.00026; one sample t test; Figure 5F), supporting the conclusion
that FOXM1 and CENPF synergistically regulate tumor growth
in vivo.
To further evaluate the synergistic activity of FOXM1 and
CENPF for tumor growth, we developed an in vivo competition
assay (Figures 5I–5K). Specifically, we infected DU145 cells
with silencing vectors expressing an FOXM1 shRNA and an
RFP reporter (red) or a CENPF shRNA and an GFP reporter
(green), or both lentiviruses (yellow; Figure 5I). As negative con-
trols, we infected DU145 cells with control vectors lacking the
FOXM1 or CENPF shRNA but expressing the fluorescent re-
porters. We then implanted equal numbers of viable red, green,
or yellow cells from the experimental or control groups into
immunodeficient mice. Following 1 month of growth in vivo,
the resulting tumors were isolated and the percentage of red,
green, and yellow cells were quantified by fluorescence-acti-
vated cell sorting.
Tumors derived from control cells (n = 4) were comprised of
equivalent numbers of red (34% ± 0.6%), green (34% ± 2.7%),
and yellow (33% ± 1.2%) cells, indicating that the respective len-
tiviral vectors offer no selective growth advantage (p % 0.614;
Hotelling’s one-sample T-squared test; Figures 5J and 5K). In
striking contrast, tumors derived from the experimental cells
(n = 7) were comprised primarily of green CENPF-silenced cells
(57% ± 3.5%) and red FOXM1-silenced cells (41% ± 2.6%),
whereas there were virtually no yellow cosilenced cells (2.0% ±
0.3%; Figures 5J and 5K). This profound selection against cells
cosilenced for FOXM1 and CENPF was highly significant (p %
0.0001; Hotelling’s one-sample T-squared test; Figure 5K),
which further supports the conclusion that FOXM1 and CENPF
synergistically regulate tumor growth in vivo.
FOXM1 and CENPF Coregulate Gene Expression and
Control Tumorigenic Signaling Pathways in Prostate
Cancer
To investigate the mechanism(s) underlying the observed activ-
ities of FOXM1 and CENPF, we assessed the consequences
of their individual versus cosilencing for expression of their
ARACNe-inferred common (shared) target genes (Table S3).
Figure 5. Functional Validation of FOXM1 and CENPF
(A) Human prostate cancer cells were infected with lentiviral silencing vectors expressing shRNA for FOXM1 and/or CENPF (or control) and either an RFP (red) or
GFP (green) reporter. Unless otherwise indicated, analyses were done using two independent shRNAs for each gene and in four independent prostate cancer cell
lines (DU145, PC3, LNCaP, 22Rv1); in most cases data using shRNA1 are shown.
(B) Western blot analysis showing expression of FOXM1 or CENPF proteins in DU145 cells with the indicated shRNAs.
(C and D) Colony formation assay. (C) Representative analyses of DU145 cells with an shRNA for FOXM1 and/or CENPF (or the control) with colonies visualized
using crystal violet. (D) Quantification of colonies using ImageJ.
(E–H) Analysis of tumor growth in vivo. (E) DU145 cells expressing an shRNA for FOXM1 and/orCENPF, or the control, were implanted subcutaneously intomouse
hosts. Beginning on day 7, mice were administered doxycycline to induce shRNA expression and tumor growth was monitored for 1 month. (F) Tumor growth
curves for the indicated shRNA. The dashed line shows the predicted additive effect of cosilencing FOXM1 and/or CENPF. (G) Tumor weights at the time of
sacrifice. (H) Representative tumors. In (D), (F), and (G) the predicted additive was estimated based on the consequences of individual silencing of FOXM1 and
CENPF using a log-linear model; the p value, calculated using a one-sample t test, indicates the significance between the predicted additive versus the actual
(observed) consequences of cosilencing FOXM1 and CENPF.
(I–K) In vivo competition assay. (I) Equal numbers of DU145 cells expressing the control shRNA (control cells), or the experimental shRNA for FOXM1 and/or
CENPF (experimental cells) as well as RFP or GFP were implanted into mouse hosts. Beginning on day 7, mice were administered doxycycline to induce shRNA
expression and tumor growth wasmonitored for 1 month, then tumors were collected and fluorescence-activated cell sorting was performed to quantify the total
number of red, green, or yellow cells in individual tumors for control and experimental groups. (J) Representative fluorescence-activated cell sorting plots showing
the percentage of red, green, or yellow cells relative to the total number of fluorescent cells. (K) (top) Graphs show the average percent of red, green, and yellow
cells in the control tumors (n = 4) or experimental tumors (n = 7); p values correspond to a Hotelling’s one-sample t test. (Bottom) Representative tumors. Error
bars represent ± SD.
See also Figure S3.
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Figure 6. FOXM1 and CENPF Synergistically Regulate Gene Expression and Control Tumorigenic Signaling Pathways in Prostate Cancer
(A) Validation of ARACNe-inferred shared targets of FOXM1 and CENPF. The graphs show relative mRNA expression levels, normalized to GADPH, for the
indicated genes in the cell lines shown following individual or cosilencing of FOXM1 and CENPF. The p values (indicated by *) show the significance of the
predicted additive effect versus actual effect on gene expression calculated using a one-sample t test (*p < 0.01; **p < 0.001).
(B) Chromatin immunoprecipitation followed by qPCR of genomic binding sites of FOXM1. Cells were infected with a lentivirus expressing V5-tagged FOXM1 as
well as an shRNA for CENPF (or a control) and ChIP was done using an anti-V5 antibody. Data are expressed as fold enrichment of FOXM1 binding normalized to
input.
(C) Subcellular localization of FOXM1 and CENPF in prostate cancer cells after silencing. Shown are microphotographs of immunofluorescence staining for
FOXM1 or CENPF in the control or silenced cells as indicated. Arrows indicate subcellular localization. Scale bars represent 1 mm.
(D and E) Consequences of silencing FOXM1 and/or CENPF for gene expression profiling in DU145 cells. (D) Heatmaps of differentially expressed genes. Colors
correspond to levels of differential expression; red corresponds to overexpression and blue to under-expression. Selected genes differentially expressed
following cosilencing are indicated. (E) Heatmaps showing leading edge genes of biological pathways enriched by cosilencing of FOXM1 andCENPF as assessed
by gene set enrichment analysis.
(F) Western blot analyses showing expression of the indicated markers of the PI3-kinase and MAP kinase signaling pathways in DU145 and PC3 prostate cancer
cells silenced for FOXM1 and/or CENPF, as indicated. Error bars represent ± SD.
See also Figure S4 and Tables S8 and S9.
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their individual silencing, cosilencing of FOXM1 and CENPF pro-
duced a significantly greater reduction for themajority of targets,646 Cancer Cell 25, 638–651, May 12, 2014 ª2014 Elsevier Inc.consistent with coregulation of target gene expression by
FOXM1 and CENPF (Figure 6A; Figure S4). Furthermore, using
chromatin immunoprecipitation (ChIP) followed by quantitative
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sites on shared target genes was reduced following silencing
of CENPF (Figure 6B), suggesting that CENPF is required for
appropriate genomic binding by FOXM1. Interestingly, although
we did not observe a direct protein-protein interaction of FOXM1
and CENPF in co-immunoprecipitation assays (data not shown),
we observed that FOXM1 and CENPF were colocalized in the
nucleus of prostate cancer cells and that their subcellular coloc-
alization was mutually dependent (Figure 6C). In particular,
silencing of CENPF resulted in the redistribution of FOXM1 to
the cytoplasm as well as the nucleus, and conversely silencing
of FOXM1 resulted in the accumulation of CENPF at the nuclear
periphery (Figure 6C). Notably, subcellular colocalization of
FOXM1 and CENPF was also observed in human prostate tu-
mors and was associated with disease outcome (see below).
Taken together, our findings suggest that FOXM1 and CENPF
coregulate expression of shared target genes in prostate cancer
cells, at least in part, through their subcellular colocalization.
To elucidate molecular pathways underlying the synergistic
interaction of FOXM1 andCENPF for tumor growth, we analyzed
expression profiles from prostate cancer cells in which they were
individually silenced or cosilenced (Figure 6D; Table S8). The
differentially expressed genes following individual silencing of
FOXM1 or CENPF included a majority of their ARACNe-inferred
targets (p = 0.0028 for enrichment of FOXM1 targets; p% 0.001
for CENPF targets), further confirming the accuracy of the
ARACNe analysis (Table S8). Inspection of these differentially
expressed genes, as well as gene set enrichment analysis of en-
riched biological pathways confirmed the known individual func-
tions of FOXM1 and CENPF as regulators of cellular proliferation
and/or mitosis (Tables S8 and S9).
However, cosilencing of FOXM1 andCENPF revealed an addi-
tional repertoire of significantly differentially expressed genes
and enriched biological pathways (Figures 6D and 6E; Tables
S8 and S9), including several pathways associated with tumori-
genesis: ‘‘cell cycle’’ (normalized enrichment score [NES] 1.32;
p% 0.001), ‘‘stress pathway’’ (NES 1.58; p% 0.01), ‘‘regulation
of insulin-like growth factor’’ (NES 1.89; p% 0.001), ‘‘signaling by
NGF’’ (NES 1.25; p% 0.001), ‘‘metabolism of amino acids’’ (NES
1.25; p % 0.01), ‘‘PI3-Akt signaling’’ (NES 1.89; p % 0.001),
‘‘MAP kinase pathway’’ (NES 1.34; p% 0.008), ‘‘telomere main-
tenance’’ (NES 1.35; p % 0.01), and ‘‘cell adhesion molecules’’
(NES 1.32; p% 0.001).
Notable was the enrichment of PI3-kinase and MAP kinase
signaling pathways following cosilencing of FOXM1 and CENPF
(Figure 6E; Table S9) because these constitute established hall-
marks of aggressive prostate cancer (Aytes et al., 2013; Taylor
et al., 2010). As evident by western blot analysis, both pathways
are completely abrogated following cosilencing of FOXM1 and
CENPF (Figure 6F), suggesting that therapeutic targeting of
FOXM1 and CENPF in prostate cancer cells may be effective
for inactivation of these signaling pathways.
Co-Expression of FOXM1 and CENPF Is a Prognostic
Indicator for Human Prostate Cancer
We next asked whether expression of FOXM1 and/or CENPF is
associated with cancer progression and/or outcome by analysis
of tissue microarrays (TMAs; Figure 7A; Table S1). In particular,
we analyzed a high-density TMA containing primary tumorsfrom a large cohort of patients (n = 916) that had undergone pros-
tatectomy at Memorial Sloan-Kettering Cancer Center (MSKCC)
from 1985 to 2003 (Donovan et al., 2008). These cases have
extensive clinical follow-up data for up to 20 years, including
time to biochemical recurrence, prostate cancer-specific sur-
vival, and time tometastasis (Table S1).We also evaluated a sec-
ond TMA from the rapid autopsy program at the University of
Michigan, which contains prostate cancer metastases (n = 60),
including 6 lung, 11 liver, 22 lymph node, and 14 other sites
(Shah et al., 2004).
Analysis of the MSKCC prostatectomy TMA revealed that
FOXM1 and CENPF were overexpressed in 33% and 37% of
all cases, respectively, (n = 821 informative cases) with a trend
toward increased expression in tumors with higher Gleason
scores (Figure 7A; Figure S5A). Furthermore, analysis of the
Michigan metastasis TMA revealed that FOXM1 and CENPF
were expressed in most of the prostate cancer metastases
(88% and 90%, respectively; n = 53 informative cases; Fig-
ure 7A). Moreover, FOXM1 and CENPF were frequently co-
expressed and colocalized in the nucleus in both the MSKCC
prostatectomy TMA (Spearman’s Rho = 0.57, p % 2 3 1016)
and the Michigan metastasis TMA (Spearman’s Rho = 0.43,
p % 1 3 103; Figure 7A). Additionally, at the mRNA level,
overexpression of FOXM1 and CENPF was well correlated in
advanced prostate cancer and metastases from independent
cohorts of human prostate cancer (Figure S5B).
To determine whether expression of FOXM1 and/or CENPF is
associated with disease outcome, we first defined four groups of
patients from the MSKCC TMA based on their expression levels:
(1) low/normal expression of both FOXM1 and CENPF (n = 418);
(2) high expression of FOXM1 and low/normal expression of
CENPF (n = 97); (3) high expression of CENPF and low/normal
expression of FOXM1 (n = 133); and (4) high expression of
both FOXM1 and CENPF (n = 173). Kaplan-Meier survival anal-
ysis revealed that patients having elevated expression of both
FOXM1 and CENPF had the worst outcome for three indepen-
dent clinical endpoints, namely, time to biochemical-free recur-
rence (p % 4.4 3 106), death due to prostate cancer (p %
5.93 109), and time to metastasis (p% 1.03 1016; Figure 7B).
Notably, subcellular colocalization of FOXM1 and CENPF in
prostate tumors was also associated with the worst outcome
for all three independent clinical endpoints (Figure S5A). In
contrast, elevated expression of only FOXM1 or CENPF was
either not significant or marginally significant for biochemical
recurrence and prostate-specific survival (p % 0.053 and p %
0.011 for FOXM1, respectively; p % 0.078 and p % 0.402 for
CENPF, respectively), and was 10 to 13 orders of magnitude
less significant for time to metastasis (p % 0.001 for FOXM1
and p% 3.1 3 106 for CENPF; Figure 7B).
We independently corroborated the association of FOXM1
and CENPF with disease outcome in two independent human
prostate cancer data sets that had not been used for training
purposes elsewhere in this study; namely, the Glinsky data set,
in which biochemical recurrence is the clinical endpoint (Glinsky
et al., 2004), and the Sboner data set, in which the clinical
endpoint is prostate cancer-specific overall survival (Sboner
et al., 2010; Table S1). Using these independent cohorts, we
evaluated the mRNA expression levels of FOXM1 and CENPF
as well as their MARINa-inferred transcriptional activityCancer Cell 25, 638–651, May 12, 2014 ª2014 Elsevier Inc. 647
Figure 7. Clinical Validation of FOXM1 and CENPF in Human Prostate Cancer
(A) Analysis of tissue microarrays (TMAs). Representative images from the MSKCC prostatectomy TMA and the Michigan metastasis TMA showing FOXM1 and
CENPF protein expression; Spearman correlation of their co-expression with p value is shown. Scale bars represent 10 mm (lower primary tumor) or 100 mm
(all others).
(B) Kaplan-Meier survival analysis based on protein expression levels of FOXM1 and CENPF in MSKCC prostatectomy TMA with respect to time to biochemical
recurrence, time to prostate cancer-specific death, or time to metastatic progression.
(C) Kaplan-Meier survival analysis based on the ARACNe-inferred activity levels of FOXM1 and CENPF (Supplemental Experimental Procedures) in two inde-
pendent human prostate cancer data sets using biochemical recurrence-free survival (Glinsky et al., 2004) or prostate cancer-specific survival (Sboner et al.,
2010) as disease endpoints. In (B) and (C), the p values correspond to a log-rank test and indicate the statistical significance of the association with outcome for
each indicated branch compared to control (i.e., patients with low activity levels of both FOXM1 and CENPF, blue line curve).
(D) C-statistics analysis, based on the protein levels of FOXM1 and CENPF from the MSKCC TMA, using death due to prostate cancer and time to metastasis as
evaluation endpoints.
See also Figure S5.
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We then performed Kaplan-Meier survival analysis comparing
four patient groups: (1) those with low inferred activity or expres-
sion for FOXM1 and CENPF; (2) those with high inferred activity
or expression only for FOXM1; (3) those with high inferred activity
or expression only for CENPF; and (4) those with high inferred
activity or expression for both FOXM1 and CENPF. Similar to
our analysis of the TMA, patients with high inferred activity or
mRNA expression for both CENPF and FOXM1 were associated
with the worst outcome in both cohorts, as measured by648 Cancer Cell 25, 638–651, May 12, 2014 ª2014 Elsevier Inc.biochemical recurrence (p % 0.000065) and prostate cancer-
specific survival (p% 0.000040; (Figures 7C and S5C). Notably,
these findings reveal that their MARINa-inferred activities are
well correlated with the actual protein expression of FOXM1
and CENPF, and further demonstrate the striking association
of their co-expression/co-activity with poor disease outcome.
Finally, association of FOXM1 and CENPF protein expres-
sion with disease outcome using C-statistics revealed its robust
prognostic value for disease-specific survival (C = 0.71; CI 0.59–
0.84, p % 0.00024), as well as time to metastasis (C = 0.77;
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sion of FOXM1 and CENPF proteins dramatically improves
prognosis over Gleason score alone for both disease-specific
survival (C = 0.86; CI 0.80–0.93, p % 1.0 3 1030; p value for
improvement p % 0.00020) and time to metastasis (C = 0.86;
CI 0.81–0.89, p % 6.5 3 1058; p value for improvement, p %
5.3 3 1013; Figure 7D). Taken together, these analyses
of independent clinical cohorts and using distinct statistical
models demonstrate that co-expression of FOXM1 and CENPF
is a robust prognostic indicator of poor disease outcome and
metastasis.
DISCUSSION
Recent advances in whole-genome analyses are providing an
increasingly high-resolution view of the multitude of genetic,
genomic, and epigenetic alterations associatedwith cancer phe-
notypes. Given the staggering number of potential interactions,
identification of the true causal drivers and essential synergistic
interactions represents a considerable challenge. In the current
study, we have demonstrated that cross-species interroga-
tion of genome-wide context-specific regulatory networks can
address this challenge by dramatically winnowing the candidate
gene interactions that implement the regulatory programs under-
lying cancer phenotypes. In particular, we have introduced a
comprehensive systems approach to interrogate complemen-
tary regulatory networks for human and mouse prostate cancer
to identify conserved causal regulators and to elucidate syner-
gistic interactions among them. These studies have led to the
identification of FOXM1 and CENPF as synergistic master regu-
lators of prostate cancer malignancy and robust prognostic bio-
markers of aggressive prostate cancer. We propose that this
overall approach for genome-wide cross-species analysis will
be generally applicable for identifying synergistic interactions
that drive physiologic and pathologic phenotypes in cancer
and other diseases.
The genome-wide assembly and cross-species interrogation
of human andmouse prostate cancer regulatory networks repre-
sents a major conceptual advance. A critical requirement was
the generation of a mouse prostate cancer interactome from a
data set of appropriate size and expression heterogeneity. We
incorporated the diversity afforded by genetically and pheno-
typically distinct mouse models of prostate cancer obtained
through a community effort (see Supplemental Experimental
Procedures), in combination with exogenous perturbations
administered to each mouse model. This strategy has led to
the successful construction of a genome-wide, context-specific
mouse interactome for the study of prostate cancer, and is
generalizable for the generation of interactomes for a wide range
of physiologic and pathologic phenotypes.
A second critical requirement was the development of
an informative algorithm to determine whether the human and
mouse prostate cancer interactomes represented conserved
regulatory programs, thus enabling accurate and robust
cross-species integrative analysis. Toward this end, we intro-
duced a metric for quantitative assessment of conservation of
regulatory networks, which revealed that the large majority of
regulatory programs represented by these networks are highly
conserved (>70%). Although the current study is focused onprostate cancer interactomes assembled using ARACNe, this
general approach for evaluating conservation can be used for
cross-species analyses of regulatory networks for other cancers
or other diseases and can be readily adapted for analyses
of networks inferred using alternative algorithms, such as those
based on the Context Likelihood of Relatedness and Bayesian-
networks algorithms (Akavia et al., 2010; Faith et al., 2007).
Indeed, we envision that the ability to quantitatively evaluate
conservation of cross-species regulatory programs will be
broadly applicable for other physiological and pathological
comparisons, and particularly beneficial for accurate integra-
tion of preclinical findings from genetically engineered mice to
human clinical trials.
A third critical requirement for the success of our approach
was our ability to effectively mine these cross-species regulatory
networks to identify conserved master regulators of cancer
malignancy and to identify their synergistic interactions. The
MARINa algorithm used for these analyses infers ‘‘master regu-
lators’’ as genes that most significantly regulate the transcrip-
tional program associated with a particular phenotype (in this
case, prostate cancer malignancy), and hence are rate-limiting
drivers of the phenotype (Carro et al., 2010; Lefebvre et al.,
2010). Notably, MARINa also provides an effective computa-
tional tool for analyses of synergistic interactions among master
regulators (Carro et al., 2010); indeed, our unbiased interrogation
of 2,000 transcriptional regulators represented in the interac-
tomes led to identification of a single synergistic pair, namely
FOXM1 and CENPF. The power of this approach suggests that
it may be of general value in dissecting polygenic dependencies
in cancer and other diseases.
Although both FOXM1 and CENPF have been implicated in
various cancers, our study has uncovered their unexpected
synergistic interaction. FOXM1 encodes a forkhead domain
transcription factor that is frequently overexpressed in many
different types of cancer, including prostate (Alvarez-Fernandez
and Medema, 2013; Halasi and Gartel, 2013a; Kalin et al., 2011;
Koo et al., 2012). Many previous studies have established a role
for FOXM1 in regulation of cellular proliferation, DNA damage,
genomic stability, drug resistance, and metastasis, and have
shown that it interacts with other key regulators such as b-cate-
nin and MYB (Lefebvre et al., 2010; Zhang et al., 2011). In pros-
tate cancer, gain- or loss-of-function of FOXM1 in vivo have been
shown to elicit modest effects on tumor growth (Cai et al., 2013;
Kalin et al., 2006).
CENPF (also known as mitosin or LEK1 in mouse), a known
target of FOXM1, has also been implicated in various cancers,
although not previously in prostate, and in some cases has
been shown to undergo gene amplification and to be associated
with disease outcome (Ma et al., 2006; Varis et al., 2006). How-
ever, the actual functional role of CENPF has been more elusive
and difficult to reconcile. In particular, whereas CENPF is named
for its association with the centromere-kinetochore protein com-
plex, such association is transient and, in fact, CENPF has other
functions, including regulation of mitosis and cellular prolifera-
tion (Bomont et al., 2005; Feng et al., 2006; Holt et al., 2005),
which are mediated in part by protein interactions (Ma et al.,
2006; Varis et al., 2006).
Thus, although the individual functions of FOXM1 and CENPF
in cancer had been well studied, their synergistic interactionCancer Cell 25, 638–651, May 12, 2014 ª2014 Elsevier Inc. 649
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latively, our findings suggest that co-expression of FOXM1 and
CENPF in prostate cancer leads to coregulation of transcrip-
tional programs, which ultimately result in activation of the key
signaling pathways associated with prostate cancermalignancy,
including the PI3K and MAPK signaling pathways. Because
FOXM1 and CENPF can each be targeted pharmacologically
(Halasi and Gartel, 2013b; Pan and Yeung, 2005; Radhakrishnan
et al., 2006), their inhibition may provide an effective means
of treating advanced prostate cancer; indeed, therapeutic tar-
geting of FOXM1 and CENPF may help overcome the complex
feedback mechanisms that have hindered therapeutic targeting
of PI3K and MAPK signaling pathways.
Furthermore, we envision that by using alternative gene
signatures that represent other prostate cancer phenotypes,
genome-wide cross-species analysis of master regulators and
their potential synergistic interactions may help to define
molecular subtypes of prostate cancer, which have thus far
been elusive. More broadly, our general approach to elucidate
conserved and functionally relevant gene interactions can be
applied tomany tumor contexts as well as other human diseases
for which appropriate model systems are available.
EXPERIMENTAL PROCEDURES
Assembly of Interactomes and Master Regulator Analyses
Expression profile data sets for human prostate cancer are described in Table
S1. GEMMs are described in Table S2 and their representative histopathology
shown in Figure S1A. A description of perturbagen treatments is provided in
the Supplemental Experimental Procedures. Human and mouse interactomes
were assembled using the ARACNe algorithm (Margolin et al., 2006a). Details
of the resulting human and mouse networks are provided in Tables S3 and S4,
respectively. Analysis of cross-species network conservation was done using
a modification of the MARINa algorithm described in the Supplemental Exper-
imental Procedures. Master regulator analysis and computational synergy
analysis were performed using MARINa (Carro et al., 2010; Lefebvre et al.,
2010). Master regulators for the human and mouse interactomes are provided
in Tables S6 and S7, respectively.
Functional Validation
Gene silencing of FOXM1 and CENPF as well as forced expression of FOXM1
were done using lentiviral shRNAs or expression vectors (Open Biosystems
and CCSB Human ORFeome Library, respectively). Human cancer cell lines
used for functional studies were obtained from ATCC. All experiments using
animals were performed according to protocols approved by the Institutional
Animal Care and Use Committee at Columbia University Medical Center.
Tissue Microarray Analyses
All studies involving human subjects were approved by the Institutional Review
Board of MSKCC or University of Michigan. TMAs were constructed with
approval from the Human Biospecimen Utilization Committee and Institutional
Review Board; consent was obtained from all patients, as required. Analysis of
protein expression of FOXM1 and CENPF was performed using a high-density
TMA (Donovan et al., 2008) and ametastasis TMA (Shah et al., 2004). Available
clinicopathological features of these TMAs are summarized in Table S1.
Statistical Methods
Statistical analysis was performed with survcomp package using R v2.14.0.
Cox proportional hazard model was estimated with the surv and coxph
functions. Kaplan-Meier survival analysis was performed using surv, survfit,
and survdiff functions. Concordance indexes (c-index) were estimated
and compared using coxp and concordance.index (counting ties) and
cindex.comp functions. Details of all statistical analyses and all computational
procedures are provided in the Supplemental Experimental Procedures. An650 Cancer Cell 25, 638–651, May 12, 2014 ª2014 Elsevier Inc.executable SWEAVE document and R data objects are deposited in Figshare
at http://dx.doi.org/10.6084/m9.figshare.928353.
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